

Table 1 Long-term outcomes of SBRT vs. lobectomy in general
 Ordered by degree of confidence that results reflect the effect of the treatment, stage

1 st author year (reference)	Study characteristics								Adjustment for confounding							Confid RE Tmt effect	f/u (mo) Surg/SBRT ^b	Adjusted % 5-yr OS SBRT vs. Lobe			Adjusted % 5-yr LCSS SBRT vs. Lobe				
	Source	Yrs	n	Stage ^a	Surg extent	Other	Mean age ^b	% Charlson score ≥ 2 ^b	Demogr F	CoMorbid	Hi stage	Time span	Q settings	Q treatmt	Fav tumor			Statistical methods	# adj for/ subsets	SBRT	Lobe	HR	SBRT	Lobe	HR
SBRT vs. lobectomy																									
Khorfan 2020 (40)	NCDB	04-16	1,547 ^c	cIA1,2	L+SL	Decl S	>70 ^d	12 ^d							PM	11/4	H	-	42	64	>1 ^e	-	-	-	
Rosen 2016 (41)	NCDB	08-12	10,914	cIA	L	CC =0	75/76 ^d	0							MV, PM	16/3	H	-	-	-	2.63	-	-	-	
Rosen 2016 (41)	NCDB	08-12	3,562 ^c	cl-IIA	L	CC =0	75/76	0							MV, PM	16/3	H	32/29	29	59	-	-	-	-	
Boyer 2017 (10)	VA	01-10	936 ^c	cl-IIA	L		67/73	27/43							MV, PA	8/6	H	93/81	27	54	1.96	50	73	2.17	
Rosen 2016 (41)	NCDB	08-12	4,519	cIB-IIA	L	CC =0	75/76 ^d	0							MV, PM	16/3	H	-	-	-	2.63	-	-	-	
Chi 2019 (42)	NCDB	04-15	85,827	T _{any} NO	L		-75 ^d	18/19 ^d							MV, PM	19/4	H	-	32 ^f	66^f	1.87	-	-	-	
Khorfan 2020 (40)	NCDB	04-16	2,630 ^c	T _{any} NO	L+SL	Decl S	>70 ^d	12 ^d							MV, PM	11/4	H	-	38	57	1.69	-	-	-	
Chang 2021 (43)	US x1	15-17	160 ^c	cIA	L ^g		69/69	0/0							PM	5	M	60	87	84	0.86	92	93	NS	
Bryant 2018 (9)	VA	06-15	2,541	cl	L		-	-							MV	12/2	M	35/18	-	-	-	-	-	1.33	
Bryant 2018 (9)	VA	06-15	3,435	cl-IIA	L		66/71	39/39							MV	12/2	M	35/18	44 ^f	70^f	1.38	55 ^f	77^f	1.45	
Sebastian 20 (44)	US x1	08-18	217 ^c	cl-IIA	L		70/70	-							PM	11	M	27/22	[56] ^h	[79]^h	2	-	-	-	
Spencer 2019 (45)	UK x1	08-13	415	cl-IIA	L+SL		70/77	-							MV	5/2	M	59/46	[47] th	[75]th	1.84	67 ^f	76^f	1.47 ⁱ	
Tomita 2021 (46)	Japan x1	04-14	240 ^c	cl-IIA	L+SL	10% GG	76/76	36/33							MV, PM	9	M	66/69	64	71	1.5	78	82	1.3	
Hamaji 2015 (47)	Japan x1	03-09	82 ^c	cl-IIA	L ^g		74/73	-							PM	9	M	54/41	37	69	2.56	56	84	4.39 ⁱ	
Dong 2020 (48)	China x1	12-16	104 ^d	cl-IIA	L ^g	Incl GG	67/68	19/23 ^k							PM	7	M	44	80	92	>1 ^e	84	92	>1 ^e	
Bryant 2018 (9)	VA	06-15	894	cIIA	L		-	-							MV	12/2	M	35/18	-	-	-	-	-	1.22	
Yu 2015 (7)	SEER	07-09	608 ^c	I-IIA ^j	L+SL	LE ≥ 5 y	>75	40/42 ^k							PM	11	L	-	-	-	1.49	-	-	1.63	
Puri 2015 (49)	NCDB	98-10	10,710	cl-IIA	L+SL		74/74	14/14							PQ, PM	9/3	L	28/17	24	51	>1 ^e	-	-	-	
Crabtree 2014 (13)	US x1	04-10	112 ^c	cl-IIA	L+SL		70/71	50/55							PM	5	L	34/23	[47] ^h	[75]^h	-	-	-	-	
Lin 2019 (50)	China x1	11-16	90 ^c	cl-IIA	L		70/69	-							PM	5	L	31/25	[80] ^h	[79] ^h	1	[80] ^h	[86]^h	>1 ^e	
Verstegen 13 (51)	Dutch x6	-	128 ^c	cl-IIA	L ^g		68/71	45/45							PM	10	L	16/30	[80] ^h	[77] ^h	.92	-	-	-	
Cornwell 2018 (52)	VA x1	09-14	74 ^c	cl-IIA	L		68/66	-							PM	10	L	30	[53] ^h	[86]^h	>1 ^e	[78] ^h	[93]^h	>1 ^e	
Dong 2019 (53)	China x1	12-17	132 ^c	cl-IIIa	L+SL	Incl GG	68/68	26/24							PM	8	L	48/31	73	83	>1 ^e	[89] ^h	[95]^h	>1 ^e	
Van den Berg (54)	Dutch x1	07-10	340	cl-IIA	L ^{m,n}		67/77	55/61							MV	6	VL	61/61	32 ^f	58^f	1.07	-	-	-	
Albano 2018 (55)	US x1	08-12	132 ^c	cl-IIA	L		66/74	-							MV, PM	5	VL	-	30	76	>1 ^e	-	-	-	
Mokhles 2015 (56)	Dutch x1	03-12	96 ^c	cl-IIA	L		67/67	47/46							PM	10	VL	54/30	53	80	>1 ^e	-	-	-	
Kastelijin 2015 (57)	Dutch x1	08-11	228	cl-IIIa	L ^m		67/72	-							PA	7	VL	42/32	18 ^f	54^f	1.7	-	-	-	

Inclusion criteria (for *Tables 1,2*): studies with multivariable or propensity adjustment of SBRT vs. surgery, 2000–21, with >50 pts per arm, general data. The HR reference is surgery (HR >1 indicates worse outcome compared with surgery). Bold highlights better outcome (>2-point difference); Light green shading highlights statistically significant differences (lighter shade = univariable; darker = multivariable); Red font indicates follow-up <24 months in at least one arm. For abbreviations, footnotes, explanation of adjustment for confounding see legend for *Table 2*.